swastic pharma and surgiclas
Tender Performance & Track Record
Company Overview
Tender Performance
Data for 01 April 2024 to 14 September 2025
Total Bids / Contract Value
Qualified Bids / Q Rate
Total Wins / Win Value
Wins Rate / Q-W Rate
Detailed Performance Analysis
Top Bid Competitors
Companies that frequently compete with you in the same tenders — ranked by their total win value.You applied for 66 bids — CAREWELL INDIA appeared in 32 of them.
SWASTIC PHARMA AND SURGICLAS
SWASTIC PHARMA AND SURGICLAS
Transform Your Tender Process
Join thousands of businesses winning more tenders
Smart Alerts
Get AI-powered tender recommendations
Market Intel
Track competitor bidding patterns
Email Reports
Weekly detailed analytics reports
Download Hub
Export tender data in bulk format
Smart Tracking
Never miss important deadlines
& Much More...
Discover all premium features with your trial
"TendersAi transformed our bidding process. We've increased our win rate by 40% and saved countless hours."
Historical Performance
7-year trend analysis (2018-2025)
Company Overview (1 Apr 2018-31 Mar 2025))
Total Bids
338
Contract Value
₹3.21 Cr
L1 Bids
105
Recent Win Rate
4.2%
Performance Analytics
SWASTIC PHARMA AND SURGICLAS: Business Analysis and Strategic Insights
Executive Summary:
Swastic Pharma And Surgiclas has demonstrated a strategic engagement in India's public procurement landscape, participating in 338 government tenders. This comprehensive business analysis provides in-depth insights into their bidding performance, tender success patterns, and competitive positioning in government contracts. Despite a historical win rate of 31.1%, recent performance indicates a concerning decline, necessitating strategic adjustments for sustained growth. Their focus on Uttar Pradesh and key organizations like Indian Railways highlights regional and sectoral specialization. Financial analysis reveals a significant contract value secured over the years, albeit with recent revenue contractions. Understanding their strengths, weaknesses, opportunities, and threats (SWOT) will be crucial for formulating effective strategies to navigate the competitive pharmaceutical tenders market.
Financial Performance Analysis
Swastic Pharma And Surgiclas's financial performance in government tenders reveals a mixed trajectory. While historically robust, recent trends indicate a need for strategic realignment. Here's a detailed breakdown:
Key Financial Metrics:
- Total Bids: 338
- Qualified Bids: 255
- L1 Bids (Wins): 105